The Competition Appeal Tribunal has unanimously upheld the CMA’s decision condemning a pharmaceutical supplier for excessive pricing of medicines sold to the NHS.
Advanz Pharma secures exclusive rights from Alvotech to commercialize five proposed biosimilars in EuropeThe agreement includes proposed biosimilars to Simponi® , Entyvio® and three. | May 24, 2023
Advanz Pharma will commercialize AVT23, a proposed biosimilar to Xolair® (omalizumab) in the European Economic Area, UK, Switzerland, Canada, Australia, and New Zealand Alvotech (NASDAQ: ALVO), a global